Featured
Cassava Sciences Stock Soared 130% on Monday Followed by Positive Results of New Alzheimer’s Phase 2 Trials
The biotech company Cassava Sciences updates that its Alzheimer’s drug, sumifilam, recorded positive results in treating Alzheimer’s patients in a